HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.

AbstractBACKGROUND:
Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement may predict the outcome of targeted drug therapy and also are associated with the efficacy of chemotherapy in patients with nonsmall cell lung cancer (NSCLC). The authors of this report investigated the relation of EGFR mutation or ALK rearrangement status and the expression of DNA repair or synthesis genes, including excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), thymidylate synthetase (TS), and breast cancer-early onset (BRCA1), as a potential explanation for these observations.
METHODS:
In total, 104 resected lung adenocarcinomas from women who were nonsmokers were analyzed concurrently for EGFR mutations, ALK rearrangements, and mRNA expression of the ERCC1, RRM1, TS, and BRCA1 genes. EGFR mutations were detected with a proprietary detection kit, ALK rearrangements were detected by polymerase chain reaction analysis, and genetic mRNA expression was detected by real-time polymerase chain reaction analysis.
RESULTS:
Of 104 patients, 73 (70.2%) had EGFR mutations, and 10 (9.6%) had ALK rearrangements. ERCC1 mRNA levels in patients who had EGFR mutations were 3.44 ± 1.94 × 10(-3) , which were significantly lower than the levels in patients who were positive for ALK rearrangements and in patients who were negative for both biomarkers (4.60 ± 1.95 × 10(-3) and 4.95 ± 2.33 × 10(-3) , respectively; P = .010). However, TS mRNA levels were significantly lower in patients who had EGFR mutations (1.15 ± 1.38 × 10(-3) vs 2.69 ± 3.97 × 10(-3) ; P = .006) or ALK rearrangements (1.21 ± 0.78 × 10(-3) vs 2.69 ± 3.97 × 10(-3) ; P = .020) than in patients who were negative for both biomarkers.
CONCLUSIONS:
NSCLC specimens that harbored activating EGFR mutations were more likely to express low ERCC1 and TS mRNA levels, whereas patients with NSCLC who had ALK rearrangement were more likely to express low TS mRNA levels.
AuthorsShengxiang Ren, Xiaoxia Chen, Peng Kuang, Limou Zheng, Chunxia Su, Jiayu Li, Bing Li, Yongshen Wang, Lu Liu, Qiong Hu, Jie Zhang, Liang Tang, Xuefei Li, Caicun Zhou, Gerald Schmid-Bindert
JournalCancer (Cancer) Vol. 118 Issue 22 Pg. 5588-94 (Nov 15 2012) ISSN: 1097-0142 [Electronic] United States
PMID22569898 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 American Cancer Society.
Chemical References
  • BRCA1 Protein
  • BRCA1 protein, human
  • DNA-Binding Proteins
  • RNA, Messenger
  • RRM1 protein, human
  • Tumor Suppressor Proteins
  • DNA
  • Thymidylate Synthase
  • EGFR protein, human
  • Receptor Protein-Tyrosine Kinases
  • Receptor, Epidermal Growth Factor
  • anaplastic lymphoma kinase
  • ERCC1 protein, human
  • Endonucleases
Topics
  • Adenocarcinoma (genetics)
  • Adult
  • Aged
  • BRCA1 Protein (genetics)
  • Carcinoma, Non-Small-Cell Lung (genetics)
  • DNA (biosynthesis)
  • DNA Repair (genetics)
  • DNA Replication (genetics)
  • DNA-Binding Proteins (genetics)
  • Endonucleases (genetics)
  • Female
  • Gene Rearrangement
  • Humans
  • Lung Neoplasms (genetics)
  • Middle Aged
  • Mutation
  • RNA, Messenger (biosynthesis)
  • Receptor Protein-Tyrosine Kinases (genetics)
  • Receptor, Epidermal Growth Factor (genetics)
  • Smoking
  • Thymidylate Synthase (genetics)
  • Tumor Suppressor Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: